Choosing the Best Trastuzumab-Based Adjuvant Chemotherapy Regimen: Should We Abandon Anthracyclines?

被引：30

作者：

Burstein, Harold J. ^{[1
]}

Piccart-Gebhart, Martine J. ^{[2
]}

Perez, Edith A. ^{[3
]}

Hortobagyi, Gabriel N. ^{[4
]}

Wolmark, Norman ^{[5
]}

Albain, Kathy S. ^{[6
]}

Norton, Larry ^{[7
]}

Winer, Eric P. ^{[1
]}

Hudis, Clifford A. ^{[7
]}

机构：

[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Inst Jules Bordet, B-1000 Brussels, Belgium

[3] Mayo Clin, Jacksonville, FL 32224 USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Allegheny Gen Hosp, Natl Surg Adjuvant Breast & Bowel Project, Pittsburgh, PA 15212 USA

[6] Loyola Univ, Chicago Stritch Sch Med, Maywood, IL 60153 USA

[7] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 18期

关键词：

BREAST-CANCER; PACLITAXEL; CONCURRENT; EFFICACY; THERAPY; TRIAL; HER2;

D O I：

10.1200/JCO.2012.42.0695

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页码：2179 / 2182

页数：4

共 19 条

[1]

Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer [J].

Bayraktar, Soley ;

Gonzalez-Angulo, Ana M. ;

Lei, Xiudong ;

Buzdar, Aman U. ;

Valero, Vicente ;

Melhem-Bertrandt, Amal ;

Kuerer, Henry M. ;

Hortobagyi, Gabriel N. ;

Sahin, Aysegul A. ;

Meric-Bernstam, Funda .

CANCER, 2012, 118 (09) :2385-2393

[2]

Bergstrom KA, 2010, 2010 AM SOC CLIN ONC

[3]

Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of intergroup trial C9741/cancer and leukemia group B trial 9741 [J].

Citron, ML ;

Berry, DA ;

Cirrincione, C ;

Hudis, C ;

Winer, EP ;

Gradishar, WJ ;

Davidson, NE ;

Martino, S ;

Livingston, R ;

Ingle, JN ;

Perez, EA ;

Carpenter, J ;

Hurd, D ;

Holland, JF ;

Smith, BL ;

Sartor, CI ;

Leung, EH ;

Abrams, J ;

Schilsky, RL ;

Muss, HB ;

Norton, L .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1431-1439

[4]

HER2 status and efficacy of adjuvant anthracyclines in early breast cancer:: A pooled analysis of randomized trials [J].

Gennari, Alessandra ;

Sormani, Maria Pia ;

Pronzato, Paolo ;

Puntoni, Matteo ;

Colozza, Mariantonietta ;

Pfeffer, Ulrich ;

Bruzzi, Paolo .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (01) :14-20

[5]

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial [J].

Gianni, Luca ;

Dafni, Urania ;

Gelber, Richard D. ;

Azambuja, Evandro ;

Muehlbauer, Susanne ;

Goldhirsch, Aron ;

Untch, Michael ;

Smith, Ian ;

Baselga, Jose ;

Jackisch, Christian ;

Cameron, David ;

Mano, Max ;

Pedrini, Jose Luiz ;

Veronesi, Andrea ;

Mendiola, Cesar ;

Pluzanska, Anna ;

Semiglazov, Vladimir ;

Vrdoljak, Eduard ;

Eckart, Michael J. ;

Shen, Zhenzhou ;

Skiadopoulos, George ;

Procter, Marion ;

Pritchard, Kathleen I. ;

Piccart-Gebhart, Martine J. ;

Bell, Richard .

LANCET ONCOLOGY, 2011, 12 (03) :236-244

[6]

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort [J].

Gianni, Luca ;

Eiermann, Wolfgang ;

Semiglazov, Vladimir ;

Manikhas, Alexey ;

Lluch, Ana ;

Tjulandin, Sergey ;

Zambetti, Milvia ;

Vazquez, Federico ;

Byakhow, Mikhail ;

Lichinitser, Mikhail ;

Angel Climent, Miguel ;

Ciruelos, Eva ;

Ojeda, Belen ;

Mansutti, Mauro ;

Bozhok, Alla ;

Baronio, Roberta ;

Feyereislova, Andrea ;

Barton, Claire ;

Valagussa, Pinuccia ;

Baselga, Jose .

LANCET, 2010, 375 (9712) :377-384

[7]

Role of Anthracyclines in the Treatment of Early Breast Cancer [J].

Gianni, Luca ;

Norton, Larry ;

Wolmark, Norman ;

Suter, Thomas M. ;

Bonadonna, Gianni ;

Hortobagyi, Gabriel N. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) :4798-4808

[8]

HER2 and response to paclitaxel in node-positive breast cancer [J].

Hayes, Daniel F. ;

Thor, Ann D. ;

Dressler, Lynn G. ;

Weaver, Donald ;

Edgerton, Susan ;

Cowan, David ;

Broadwater, Gloria ;

Goldstein, Lori J. ;

Martino, Silvana ;

Ingle, James N. ;

Henderson, I. Craig ;

Norton, Larry ;

Winer, Eric P. ;

Hudis, Clifford A. ;

Ellis, Matthew J. ;

Berry, Donald A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (15) :1496-1506

[9]

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer [J].

Joensuu, H ;

Kellokumpu-Lehtinen, P ;

Bono, P ;

Alanko, T ;

Kataja, V ;

Asola, R ;

Utriainen, T ;

Kokko, R ;

Hemminki, A ;

Tarkkanen, M ;

Turpeenniemi-Hujanen, T ;

Jyrkkiö, S ;

Flander, M ;

Helle, L ;

Ingalsuo, S ;

Johansson, K ;

Jääskeläinen, A ;

Pajunen, M ;

Rauhala, M ;

Kaleva-Kerola, J ;

Salminen, T ;

Leinonen, M ;

Elomaa, I ;

Isola, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (08) :809-820

[10]

Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib [J].

Morris, Patrick G. ;

Chen, Carol ;

Steingart, Richard ;

Fleisher, Martin ;

Lin, Nancy ;

Moy, Beverly ;

Come, Steven ;

Sugarman, Steven ;

Abbruzzi, Alyson ;

Lehman, Robert ;

Patil, Sujata ;

Dickler, Maura ;

McArthur, Heather L. ;

Winer, Eric ;

Norton, Larry ;

Hudis, Clifford A. ;

Dang, Chau T. .

CLINICAL CANCER RESEARCH, 2011, 17 (10) :3490-3499

← 1 2 →